These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

338 related articles for article (PubMed ID: 26852073)

  • 1. Therapeutic Potential of Cannabinoids in Psychosis.
    Leweke FM; Mueller JK; Lange B; Rohleder C
    Biol Psychiatry; 2016 Apr; 79(7):604-12. PubMed ID: 26852073
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Human Laboratory Studies on Cannabinoids and Psychosis.
    Sherif M; Radhakrishnan R; D'Souza DC; Ranganathan M
    Biol Psychiatry; 2016 Apr; 79(7):526-38. PubMed ID: 26970363
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of the Endocannabinoid System in the Pathophysiology of Schizophrenia: Implications for Pharmacological Intervention.
    Leweke FM; Mueller JK; Lange B; Fritze S; Topor CE; Koethe D; Rohleder C
    CNS Drugs; 2018 Jul; 32(7):605-619. PubMed ID: 30022465
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A systematic review of the antipsychotic properties of cannabidiol in humans.
    Iseger TA; Bossong MG
    Schizophr Res; 2015 Mar; 162(1-3):153-61. PubMed ID: 25667194
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cannabidiol as a potential treatment for psychosis.
    Schubart CD; Sommer IE; Fusar-Poli P; de Witte L; Kahn RS; Boks MP
    Eur Neuropsychopharmacol; 2014 Jan; 24(1):51-64. PubMed ID: 24309088
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Therapeutic potential of cannabinoids in schizophrenia.
    Kucerova J; Tabiova K; Drago F; Micale V
    Recent Pat CNS Drug Discov; 2014 Apr; 9(1):13-25. PubMed ID: 24605939
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cannabidiol as a treatment option for schizophrenia: recent evidence and current studies.
    Schoevers J; Leweke JE; Leweke FM
    Curr Opin Psychiatry; 2020 May; 33(3):185-191. PubMed ID: 32073423
    [TBL] [Abstract][Full Text] [Related]  

  • 8. It's All in the Rhythm: The Role of Cannabinoids in Neural Oscillations and Psychosis.
    Skosnik PD; Cortes-Briones JA; Hajós M
    Biol Psychiatry; 2016 Apr; 79(7):568-77. PubMed ID: 26850792
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cannabinoids in pain management: CB1, CB2 and non-classic receptor ligands.
    Davis MP
    Expert Opin Investig Drugs; 2014 Aug; 23(8):1123-40. PubMed ID: 24836296
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Plant-derived natural therapeutics targeting cannabinoid receptors in metabolic syndrome and its complications: A review.
    Patil AS; Mahajan UB; Agrawal YO; Patil KR; Patil CR; Ojha S; Sharma C; Goyal SN
    Biomed Pharmacother; 2020 Dec; 132():110889. PubMed ID: 33113429
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cannabinoids and schizophrenia: therapeutic prospects.
    Robson PJ; Guy GW; Di Marzo V
    Curr Pharm Des; 2014; 20(13):2194-204. PubMed ID: 23829368
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Short-and long-term effects of cannabinoids on memory, cognition and mental illness].
    Sagie S; Eliasi Y; Livneh I; Bart Y; Monovich E
    Harefuah; 2013 Dec; 152(12):737-41, 751. PubMed ID: 24483000
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cannabinoids and psychosis.
    D'Souza DC
    Int Rev Neurobiol; 2007; 78():289-326. PubMed ID: 17349865
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The endocannabinoid system and schizophrenia: links to the underlying pathophysiology and to novel treatment approaches.
    Gupta S; Cahill JD; Ranganathan M; Correll CU
    J Clin Psychiatry; 2014 Mar; 75(3):285-7. PubMed ID: 24717381
    [No Abstract]   [Full Text] [Related]  

  • 15. Cannabidiol and Sodium Nitroprusside: Two Novel Neuromodulatory Pharmacological Interventions to Treat and Prevent Psychosis.
    Crippa JA; Hallak JE; Abílio VC; de Lacerda AL; Zuardi AW
    CNS Neurol Disord Drug Targets; 2015; 14(8):970-8. PubMed ID: 26350340
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting the endocannabinoid system: future therapeutic strategies.
    Aizpurua-Olaizola O; Elezgarai I; Rico-Barrio I; Zarandona I; Etxebarria N; Usobiaga A
    Drug Discov Today; 2017 Jan; 22(1):105-110. PubMed ID: 27554802
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mid-term and long-term efficacy and effectiveness of antipsychotic medications for schizophrenia: a data-driven, personalized clinical approach.
    Glick ID; Correll CU; Altamura AC; Marder SR; Csernansky JG; Weiden PJ; Leucht S; Davis JM
    J Clin Psychiatry; 2011 Dec; 72(12):1616-27. PubMed ID: 22244023
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Could cannabidiol be used as an alternative to antipsychotics?
    Fakhoury M
    J Psychiatr Res; 2016 Sep; 80():14-21. PubMed ID: 27267317
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Exposure to cannabinoids can lead to persistent cognitive and psychiatric disorders.
    Krebs MO; Kebir O; Jay TM
    Eur J Pain; 2019 Aug; 23(7):1225-1233. PubMed ID: 30793421
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Aripiprazole in schizophrenia and schizoaffective disorder: A review.
    Stip E; Tourjman V
    Clin Ther; 2010; 32 Suppl 1():S3-20. PubMed ID: 20152550
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.